COMPANY RESEARCHCID-078, from the MXMO macrocycle platform, is an oral cyclin A/B RxL inhibitor in Phase 1; CID-165 targets cyclin D1.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
CID-078, from the MXMO macrocycle platform, is an oral cyclin A/B RxL inhibitor in Phase 1; CID-165 targets cyclin D1.
The September financing announcement supplies a Q1 2027 clinical-start target, rather than evidence that dosing has begun.
2025-12-17: Circle nominates oral cyclin D1 macrocycle CID-165 as development candidate
2026-09-16: Circle raises $92.5 million Series E for oral cyclin D1 macrocycle development
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| CID-078 | Cyclin A/B RxL · Solid tumors | Phase 1 | Clinical programs exist; complete human results were not rechecked in this review |
| CID-165 | Cyclin D1 RxL · Hematologic malignancies / solid tumors | Preclinical | Clinical programs exist; complete human results were not rechecked in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Circle Pharma raised $92.5 million in Series E financing led by The Column Group, with investors including Eli Lilly. Proceeds prioritize CID-165, an oral macrocyclic cyclin D1 RxL inhibitor planned to enter clinical development in the first quarter of 2027, and support the broader pipeline. Reported CID-165 antitumor activity remains preclinical.
Circle Pharma nominated CID-165, an orally available macrocyclic cyclin D1 RxL inhibitor, as the development candidate for its second oncology program. Preclinical studies supported disruption of the cyclin D1–Rb interaction and activity alone or with other therapies. Candidate nomination is a discovery-to-development milestone, not IND authorization or evidence that human dosing has begun.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
